Roche gives timeline for its anti-PD-L1

Roche (SIX:ROG; OTCQX:RHHBY) reported 1Q15 earnings Wednesday and discussed clinical and regulatory plans for its anti- PD-L1 candidate MPDL3280A. The company said it plans to submit a regulatory application in 2016 for MPDL3280A to treat non-small cell lung cancer (NSCLC). Roche said Monday it would begin a Phase III trial next half of the candidate to treat triple-negative breast cancer (TNBC) (see BioCentury Extra, April 20).

Roche also said it will use FoundationOne from partner Foundation Medicine Inc. (NASDAQ:FMI) to analyze tumors in its Phase III program for MPDL3280A. FoundationOne is a laboratory-developed test (LDT) for profiling genomic alterations in solid tumors (see BioCentury Extra, Jan. 12). ...